文献速递临床试验与 GCP

芪参颗粒治疗慢性心力衰竭患者的安全性和有效性:随机对照试验的研究方案

Safety and efficacy of Qishen granules in patients with chronic heart failure: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-10-10

本研究为随机、安慰剂对照、多中心、双盲、平行组临床试验,计划招募200例慢性心力衰竭患者,按1:1随机分配至芪参颗粒组或安慰剂组,每日两次给药12周。主要结局为治疗12周内NT-proBNP水平下降超过30%的患者比例,次要结局包括复合心脏事件、NYHA心功能分级、6分钟步行距离、左心室射血分数、生活质量和中医证候积分。

要点

  • 芪参颗粒是中医用于治疗慢性心力衰竭的中药复方,动物实验显示可缓解心衰症状,但缺乏标准临床试验证实。
  • 本试验为随机、安慰剂对照、多中心、双盲、平行组设计,计划纳入200例慢性心力衰竭患者,1:1随机分组。
  • 主要结局为12周治疗期间NT-proBNP水平下降超过30%的患者比例,旨在为临床应用提供高质量证据。

核心结论

  • 在标准治疗基础上,芪参颗粒可能进一步降低NT-proBNP水平。
  • 本试验将为芪参颗粒治疗慢性心力衰竭的有效性和安全性提供高质量证据,为临床应用提供参考。

研究设计与样本

  • 本研究为随机、安慰剂对照、多中心、双盲、平行组临床试验。
  • 计划招募200例慢性心力衰竭患者,按1:1比例随机分配至芪参颗粒治疗组或安慰剂组。
  • 患者每日接受芪参颗粒或安慰剂颗粒两次,持续12周。
  • 试验注册于ClinicalTrials.gov,注册号NCT03027375,注册日期2017年1月16日。

关键数值与推荐

  • 主要结局为治疗12周内NT-proBNP水平下降超过30%的患者比例,比较芪参颗粒组与安慰剂组。
  • 次要结局包括复合心脏事件、纽约心脏协会功能分级、6分钟步行距离、左心室射血分数、患者生活质量和中医证候积分量表。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic heart failure (CHF), the final stage of various cardiovascular diseases, is a major public health problem resulting in significant hospitalization rates, mortality, and huge health care costs despite advances in the treatment and management of heart failure and heart failure-related risk factors. Qishen granules (QSG), a Chinese herbal formula, is widely used by traditional Chinese medicine (TCM) practitioners to treat CHF. Several animal experimental studies have showed that QSG can significantly relieve the heart failure symptoms in CHF rat models. However, there is as yet no standard clinical trial to confirm this. Thus, the investigators are conducting this study to evaluate the efficacy and safety of QSG in a large, and varied population. METHODS/DESIGN: This study is designed as a randomized, placebo-controlled, multi-center, double-blind clinical trial with parallel groups. A total of 200 patients with CHF will be recruited and randomly allocated to either the QSG treatment group or the placebo group (in a 1:1 ratio). The patients will receive QSG or placebo granules twice a day for 12 weeks. The primary outcome is the proportion of patients in the QSG group, compared with the placebo group, demonstrating a more than 30% decrease in NT-proBNP level during 12 weeks of treatment. The secondary outcomes consist of composite cardiac events, New York Heart Association functional classification, 6-minute walking distance, left ventricular ejection fraction, patient quality of life, and the TCM syndrome integral scale. DISCUSSION: On a background of standard treatment, QSG may further reduce the levels of NT-proBNP. This trial will provide high-quality evidence on the efficacy and safety of QSG in treating CHF, thus providing reference for clinical application of QSG. TRIAL REGISTRATION: Clinical Trials.gov: NCT03027375 . Registered on 16 January 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wang J, Shi J, Wei J, et al. Safety and efficacy of Qishen granules in patients with chronic heart failure: study protocol for a randomized controlled trial. Trials. 2017. PMID: 29017565. doi:10.1186/s13063-017-2193-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。